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ABSTRACT 
Background: Metabolic disorders are well known risk factors for HCC. Conversely, their impact on 
the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic 
disorders on clinical features, treatment and survival of HCC patients regardless of its etiology. 
 
Methods: We analyzed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. 
The following metabolic features were analyzed: BMI, diabetes, arterial hypertension, 
hypercholesterolemia and hypertriglyceridemia. According to these features, patients were divided 
into 3 groups: 0-1, 2 and 3-5 metabolic features.  
 
Results: As compared with patients with 0-1 metabolic features, patients with 3-5 features showed 
lower percentage of HCC diagnosis on surveillance (p=0.021), larger tumors (p=0.038), better liver 
function (higher percentage of Child-Pugh class A [p=0.007] and MELD<10 [p=0.003]), higher 
percentage of metastasis (p=0.024), and lower percentage of portal vein thrombosis (p=0.010). The 
BCLC stage and treatment options were similar among the 3 groups, with the exception of a less 
frequent access to loco-regional therapies for BCLC stage B patients with 3-5 features (p=0.012). 
Overall survival and survival according to BCLC stage and/or treatment did not significantly differ 
among the 3 groups. Only using a probabilistic sensitivity analysis, diabetic patients showed a lower 
survival (p=0.046). MELD score, HCC morphology, nodule size, BCLC stage, portal vein thrombosis 
and metastasis were independent predictors of lead-time adjusted survival. 
 
Conclusions: Our “real world” study suggests that metabolic disorders shapes the clinical 
presentation of HCC but do not seem to play a major role in setting patient survival. 
 
Abstract Key words: Hepatocellular carcinoma, Metabolic syndrome, Diabetes, Obesity 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Key points: 
 The causal association between metabolic syndrome and HCC has been largely documented. 
 There are well established pathophysiological mechanisms linking obesity, diabetes and 
HCC. 
 Metabolic features shapes the clinical presentation of HCC but do not seem to play a major 
role in setting patient survival. 
 Diabetes seems to reduce only marginally the survival of HCC patients according to a 
probabilistic sensitivity analysis. 
 
Introduction 
The incidence of hepatocellular carcinoma (HCC) is increasing in Europe [1]. Chronic infection with 
hepatitis C virus (HCV), hepatitis B virus and excessive alcohol consumption are the major risk 
factors in industrialized countries [2]. However, in concert with the recent epidemic of obesity and 
metabolic syndrome in developed countries, the incidence and prevalence of nonalcoholic fatty liver 
disease (NAFLD) and nonalcoholic steatohepatitis (NASH) [3,4] have also increased, and today they 
represent rapidly growing causes of end-stage liver disease and HCC [5-7]. Moreover, regardless of 
the etiology of liver disease, metabolic disorders, such as obesity and diabetes, contribute to hepato-
cancerogenesis [8-10]. Indeed, there are well established pathophysiological mechanisms linking 
obesity, diabetes and HCC [11,12]. In obese individuals, the relative risk of HCC is higher than that of 
other cancer [13], and the cumulative incidence of HCC in diabetic patients is three times higher than 
in non diabetic patients [7]. Both obesity and diabetes are components of the metabolic syndrome 
(MS) [14,15], characterized by the presence of central obesity, dyslipidemia, diabetes, arterial 
hypertension [16]. The causal association between MS and HCC has been largely documented [17-
20], whereas the impact of different metabolic features (obesity, diabetes mellitus, hypertension, 
hypertriglyceridemia and hypercholesterolemia) on clinical presentation, natural history, management 
and prognosis of HCC has been less investigated. We therefore conducted a field-practice study, 
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reporting the 2009-2014 experience of the Italian Liver Cancer (ITA.LI.CA) group, aimed at 
evaluating the impact of metabolic disorders on clinical features, treatment and survival of patients 
with HCC. 
 
Materials and methods 
We retrospectively analyzed data of the Italian Liver Cancer (ITA.LI.CA) database. This registry 
collects data generated by the field-practice of 21 Italian centers spread throughout the Country 
between January 1987 and December 2014. Patients’ data are collected prospectively and updated 
every 2 years. Data entry is regularly checked for consistency by the group coordinator and when 
clarification or additional information are deemed necessary, relevant cases are resubmitted to the 
recruitment center before final inclusion in the database. The ITA.LI.CA database management 
conforms to the past and the current Italian legislation regarding privacy and the present study 
conforms to the ethical guidelines of the Declaration of Helsinki. Approval for the study was obtained 
from the Institutional Review Board of the participating centers. Details on the ITA.LI.CA database 
management have been already reported [21]. 
For the purpose of this study, we analyzed the data of 1950 cirrhotic HCC patients, consecutively 
examined and managed during 5 years, from January 2009 to December 2014, in order to analyze the 
updated managing of HCC and to avoid any interference related to the use of the new direct acting 
antivirals (DAAs) for HCV treatment. Of them, 839 meet the selection criterion, i.e. the availability of 
all data for a metabolic evaluation.  
No difference was detected in 1111 excluded patients (compared to 839 patients) in terms of age, 
gender, BMI, Diabetes, Child-Pugh Class, BCLC stage, alpha-fetoprotein (AFP) levels and performed 
treatments by means of Univariate Statistical Analysis. 
Liver disease was considered hepatitis virus C (HCV) or hepatitis virus B (HBV)-related if patients 
carried anti-HCV antibodies or HBV surface antigen (HBsAg), respectively. Liver disease etiology 
was considered alcoholic if men consumed > 40g and female > 30g per day of alcohol for > 10 years, 
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and no other causes of liver damage were found. Patients were classified as having NAFLD if all 
other known etiologies of liver disease could be ruled out and if consistent present or past histological 
or ultra-sonographic features of fatty liver and alcohol intake < 30g/ day were present. 
Demographic characteristics, liver function tests, HCC features, body mass index (BMI), presence of 
comorbidities, diabetes mellitus (fasting plasma glucose > 125mg/dl or antidiabetic therapy), 
hypertension (blood pressure > 140/90mmHg or anti-hypertensive therapy), hypertriglyceridemia 
(triglycerides > 150mg/dl) and hypercholesterolemia (cholesterol > 200mg/dl) were collected. No data 
about treatment for diabetes, hypertension or hyperlipidemia was available. 
The diagnosis of HCC was based on the European Association for the Study of Liver (EASL) [22] or 
American Association for the Study of Liver Diseases (AASLD) [23] guidelines for HCC 
management.  
Treatment options were considered according to the Barcelona-Clinic Liver Cancer (BCLC) staging 
system and their update when possible [24-25]. After 2011, the patient management followed the 
recommendations released by the Italian Association for the Study of the Liver (AISF) [26]. In each 
center, treatment decisions were taken by a multidisciplinary team, and were influenced by several 
factors, including comorbidities, specific contraindications for each procedure, local transplant criteria 
and patient’s opinion. In particular, liver transplantation was also evaluated in the setting of a down-
staging protocol [27] or a program using expanded selection criteria [28]. Patients were defined 
suitable for surgical resection according to the following criteria: single nodule or few contiguous 
nodules in the presence of a preserved liver function (Child-Pugh class A, MELD score ≤ 10); no 
evidence of portal vein infiltration or thrombosis, no evidence of extrahepatic metastasis, no general 
contraindications to surgery. Patients were defined suitable for local ablation (radiofrequency 
ablation, laser thermal ablation, percutaneous ethanol injection, cryoablation) in case of non-
resectable nodules ≤ 4 cm in size and with no more than 4 lesions. Trans-catheter arterial 
chemoembolization (TACE) was indicated in paucifocal HCC not treatable with local ablation or 
multifocal HCC, involving less than 40% of the liver volume, Child-Pugh A-B, no portal vein 
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infiltration or thrombosis, no extrahepatic metastasis, no severe associated diseases, no general 
contraindications to TACE. Systemic therapy with sorafenib was indicated in advanced HCC, Child-
Pugh A, adequate hematologic, hepatic and renal function, no severe associated diseases, no 
contraindications to sorafenib. Best supportive care (BSC) or different treatment options were 
considered in patients not amenable to (or refusing) the above mentioned treatments. 
As a diagnosis of MS was not possible to make according to the data reported in the ITA.LI.CA. 
database, the presence of the following 5 different metabolic features was analyzed: BMI ≥ 25, 
diabetes, hypertension, hypercholesterolemia and hypertriglyceridemia. According to the number of 
metabolic features, the patients were divided into 3 groups: 
• Group 1: 0-1 metabolic features; 
• Group 2: 2 metabolic features; 
• Group 3: 3-5 metabolic features. 
The section about the statistical analysis methodology is reported as supplementary methodology. 
 
Results 
Relationship among tumor burden, liver function and metabolic features 
Baseline demographics, clinical and laboratory characteristics of patients are summarized in Table 1. 
The majority of patients were males (654/839-78%), and median age was 69 years (IQR 62-75 years). 
All the enrolled patients had cirrhosis. Viral etiology accounted for the majority (58%) of cases, 
followed by metabolic etiology (23%) and alcoholic etiology (19%). BMI was ≥ 25 and < 30 
(overweight) in 467 patients (56%) and ≥ 30 (obesity) in 105 (13%). Moreover, 343 (41%) patients 
were diabetic, 393 (48%) had arterial hypertension and 171 (23%) hypercholesterolemia and/or 
hypertriglyceridemia. 
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HCC developed in a setting of well-compensated liver cirrhosis (Child-Pugh class A) in 66% of cases 
and it was detected during a surveillance program in 430 patients (51%).According to BCLC staging 
system,44% of patients were included in early or very-early stages, 18% in the intermediate 
stage,30% in the advanced stage, and 8% in the terminal stage. Regarding HCC morphology, 403 
patients had a single nodule (50%), 337 a multinodular (41%), 51 an infiltrating (6%) and 25 patients 
a massive (>10cm)(3%) tumor. The mean size of the main nodule was 3 cm (range 2-5). Metastasis 
and neoplastic portal vein thrombosis were present in 6% and 18% of cases, respectively. 
Table 2 reports the characteristics of the 3 metabolic groups of patients. 
Overall, the groups of patients significantly differed for several clinical features, according to the 
Kruskal-Wallis analysis (Table2). As compared with Group 1 (reference group), patients with ≥ 3 
metabolic disorders (outcome B) had higher prevalence of metabolic etiology (41% vs 9%, p<0.001), 
better liver function (Child-Pugh A, 72% vs 60%, p=0.007, and MELD < 10, 70% vs 59%, p=0.003), 
higher percentage of metastasis (9% vs 5%, p=0.024), lower percentage of HCC diagnosis on 
surveillance (46% vs 55%, p=0.021), larger tumors (3 cm vs 2.7 cm, p=0.038), lower percentage of 
portal vein thrombosis (14% vs 22%, p=0.010), higher platelet count (137000/ml vs 109000/ml, 
p<0.001), and lower AFP levels (8 ng/ml vs17 ng/ml, p=0.004).Differently, as compared with Group 
1, patients with 2 metabolic disorders (outcome A) significantly differ for the following features: age, 
Child-Pugh class, MELD score, AFP levels, size of the largest nodule, and presence of portal vein 
thrombosis and metastasis. Finally, the comparison of Group 2 with Group 3 (outcome C) did not 
show significant differences except for the presence of metastasis (Table2). Despite these differences, 
the distribution of BCLC stages did not differ among the metabolic groups, due to the high 
heterogeneity of patients included in each stage of this classification. 
 In order to scrutinize the role played by metabolic disorders on the access to treatment options, a sub-
analysis by BCLC stage was performed (Table 3).The only significant difference was found in BCLC 
stage B, where patients with ≥ 3 metabolic features had a less frequent access to loco-regional 
therapies and TACE as compared to Group 1 (47% vs 62%, p=0.012).This imbalance was associated 
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with a tendency toward a more frequent access to surgery (23% vs 15%), although the difference did 
not reach the statistical significance. 
 
Survival analysis 
Over a median follow-up of 26 months (IQR 11-42months), 369 (44%) patients died: 165 (48%) in 
Group 1, 84 (43%) in Group 2 and 120 (41%) in Group 3. 
The causes of death did not differ among groups (p=0.081) and were: cancer progression (45% in 
Group 1, 38% in Group 2 and 49% in Group 3, p=0.290), hepatic failure (22%,17% and 19%, 
respectively, p=0.538), hemorrhage (3%, 5% and 0%, p=0.036), infection (1%, 1% and 3%, p=0.450), 
renal failure (1%, 3% and 1%, p=0.155), other causes (28%, 36% and 28%, p=0.403). 
In the whole population, the 75
th
 centile OS was 14±1.2 months.After lead-time adjustment, the 75
th
 
centile OS decreased to 13±1.1 months. Survival rates at 1, 3 and 5 years were 76 ± 1.5%, 54 ± 1.9% 
and 49 ± 2.0%, respectively. After lead-time adjustment, these figures slightly decreased to 75 ± 
1.5%, 52 ± 1.9% and 49 ± 2.0%, respectively. 
The 75
th
 centile OS did not significantly differ among the 3 groups, both before lead-time adjustment 
(8 ± 1.7 for Group 1; 13 ± 2.6 for Group 2; 16 ± 1.5 for Group 3; p=0.075) and after lead-time 
adjustment (8 ± 1.5 for Group 1; 12 ± 2.4  for Group 2; 15 ± 1.5 for Group 3; p=0.075). Survival rates 
at 1, 3 and 5 years in the 3 groups did not significantly differ also after lead-time adjustment (Figure 
1). 
The 75
th
 centile OS according to BCLC stage did not significantly differ among the 3 groups, both 
before and after lead-time adjustment (Suppl. Figure 1). 
Furthermore, using a probabilistic sensitivity analysis approach, we evaluated the impact of five main 
metabolic features on survival: diabetes, obesity, arterial hypertension, hypercholesterolemia and 
hypertriglyceridemia. This analysis showed that diabetes marginally reduced the OS (p=0.046), while 
obesity, hypercholesterolemia, arterial hypertension and hypertriglyceridemia did not have a 
significant impact on prognosis (p=0.269, p=0.802, p=0.602, p=0.643 respectively). 
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Univariate and multivariate analysis 
In the whole population, at univariate analysis MELD score, BCLC stage, HCC morphology, nodule 
size, portal vein thrombosis, metastasis and diagnosis outside surveillance, but not male sex, age, 
etiology and presence of metabolic RFs were associated with the lead-time adjusted OS (Table 4, 
section 1). 
Therefore, we launched 3 multivariate models, including separately BCLC stage or portal vein 
thrombosis or metastasis (the last two being component of BCLC staging system).Variables 
independently associated with the lead-time adjusted OS in all the three models were: MELD score > 
10, HCC morphology and nodule size. In addition, BCLC stage B-C, portal vein thrombosis or 
metastasis independently predicted the lead-time adjusted OS in the pertinent model (Table 4, section 
1). 
The same statistical procedures were repeated in the 3 metabolic groups. In Group 1, at univariate 
analysis MELD score > 10, BCLC stage B-C, HCC morphology, nodule size, portal vein thrombosis, 
metastasis and diagnosis outside surveillance were associated with the lead-time adjusted OS, while 
the multivariate models selected as independent prognostic factors MELD score > 10 and HCC 
morphology in all the three models, and BCLC stage B-C or portal vein thrombosis in model 1 and 
model 2, respectively (Table 4, section 2). 
In Group 2, at univariate analysis, MELD score > 10, BCLC stage B-C, HCC morphology, nodule 
size, portal vein thrombosis, and diagnosis outside surveillance were associated with the lead-time 
adjusted OS, while only BCLC stage B-C and nodule size in model 1, and portal vein thrombosis in 
model 2 were independently associated with the lead-time adjusted OS at the multivariate models 
(Table 4, section 3). 
In Group 3, at univariate analysis MELD score > 10, BCLC stage B-C, HCC morphology, nodule 
size, presence of portal vein thrombosis and of metastasis were associated with the lead-time adjusted 
OS, while the multivariate models selected as independent predictors the HCC morphology in all the 
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three models and the BCLC class B-C and portal vein thrombosis and metastasis in each pertinent 
model (Table 4, section 4). 
 
Discussion  
Features of the metabolic syndrome, such as diabetes and obesity, have been associated with both 
increased risk of cancer development and cancer-related mortality regarding both gastrointestinal 
(colorectal, esophagus, stomach, and pancreas) and extra-intestinal (kidney and breast) malignancies 
[29-30]. The increased oncologic risk would be due to a number of molecular mechanisms (insulin 
resistance, chronic inflammation, reduced apoptosis, and imbalance of gut microbiota) that initiate 
and fuel carcinogenesis. In recent years, several studies have shown a strong correlation also between 
metabolic features and the development of HCC. In particular, the presence of diabetes would 
increase the incidence and aggressiveness of HCC [12,14]. However, studies describing the impact of 
metabolic disorders on clinical presentation, management and survival of patients with HCC are 
lacking. 
Our study showed that, at the time of HCC diagnosis, cirrhotic patients with ≥ 3 disorders had 
a more preserved liver function than those with no or one metabolic risk factors, suggesting that, in 
metabolic patients, HCC develops at an earlier stage of underlying liver disease. This information is in 
line with the data reported in literature, showing that in NAFLD patients HCC frequently occurs 
before the appearance of liver cirrhosis [18,31]. Moreover, we found that these patients more 
frequently presents with an advanced stage of tumor, as documented by the larger nodule size and the 
higher frequency of metastasis, even if with a lower frequency of portal vein thrombosis. This dismal 
oncologic presentation can be fundamentally attributed to the lower use of surveillance as compared 
to viral patients. However, it might also reflect a “reinforced” carcinogenesis and faster neoplastic 
progression related to hyperinsulinemia, lipotoxicity, oxidative stress and imbalance in the relative 
proportion of pro-inflammatory/anti-inflammatory cytokines [31-33]. 
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We also observed no differences in the access to therapies by the presence of metabolic 
disorders with the exception of BCLC B stage, where patients with several metabolic disorders less 
frequently underwent ablative/trans-arterial treatments and a slightly greater access to surgical 
therapies in comparison to those without metabolic problems. This shift toward surgical procedures, 
and principally to hepatic resection, is probably related to the better liver function and the larger size 
of the tumor we found in these patients. Since there is no similar data in the literature, larger and 
dedicated studies are required to confirm that metabolic comorbidities prompt a treatment shift toward 
surgery in HCC patients. 
The survival rates of our patients at 1, 3 and 5 years was 75% ± 1.5, 52% ± 1.9 and 49% ± 
2.0, respectively. These data are comparable with those already reported in literature in Italy and 
worldwide [1, 34, 35]. The survival analysis showed no impact of metabolic features even after lead 
time adjustment. The absence of impact on survival was confirmed also when survival analysis was 
made according to BCLC stage. This finding could be explained by the fact that the adverse impact on 
survival of metabolic disorders was counterbalanced by the occurrence of HCC at an earlier stage of 
underlying liver disease with respect to patients without o with an incomplete metabolic syndrome. 
In addition, the study allowed us to perform a cross-sectional evaluation of the impact of the 
five main metabolic features (diabetes, obesity, arterial hypertension, hypercholesterolemia and 
hypertriglyceridemia) on survival with a probabilistic sensitivity analysis approach. This analysis 
showed that only diabetes marginally reduces the overall survival of HCC patients. Our result 
supports and extends to Western HCC patients - managed in an updated way - the findings of quite 
old studies usually based on small surgical cohorts of Asiatic patients, reporting an adverse impact of 
diabetes on the outcome of patients with cirrhosis and HCC [36-40]. Nevertheless, despite these 
evidences and the well know pathogenic role of diabetes on cardiac, renal, and neurologic diseases, 
other studies report a better prognosis of patients with HCC and diabetes as compared to non-diabetic 
patients [8, 41]. This surprising and difficult to understand discrepancy probably relies on the effect of 
selection biases and confounding factors on results. Therefore, future studies on this topic should take 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
into account, for instance, insulin and hypoglycemic drugs (in particular metformin that seems to have 
strong antineoplastic effects [42, 43]) as factors potentially capable to influence results. 
Finally, the multivariate analysis selected BCLC stage as the only factor related to OS in 
Group 1 and 2, whereas, in Group 3, the prognosis was dictated by HCC morphology, portal vein 
thrombosis and presence of metastasis. Taken together, these results indicate that metabolic disorders 
per se do not play a crucial role in survival, despite their effects on clinical picture of HCC, as 
recently reported by Labenz et al. in the subgroup of HCC patients treated with sorafenib [44]. 
  This study presents some limitations. First, this is a retrospective and multicenter study and therefore 
it may suffer of unintended biases (for example, treatment choice influenced by different local 
facilities or conviction of the HCC team leader). Second, the incomplete clinical and laboratory 
information, for about 60% of our initial population, limit the complete transferability of our results to 
the whole patient population. However, it should be pointed out that enrolled and excluded patients 
did not differ for main clinical characteristics, as resulted comparing the two groups by means of 
univariate statistical analysis. Third, a selection bias may derive from the fact that ITA.LI.CA centers 
include hospital and academic centers in which surveillance programs are well applied and, for this 
reason, only a 30% of our patients had an advanced HCC. In particular, a high adherence rate to 
current recommendations for surveillance of at high risk patients likely favored, in terms of cancer 
presentation and survival, cirrhotic patients (particular the viral ones) rather than non-cirrhotic 
metabolic patients (who do not represent a group to be surveyed). However, we tried to minimalize 
this unavoidable bias by the adjustment of survival for the lead-time and by assessing survival in each 
BCLC stage. 
In conclusions our study, conducted on a large series of cirrhotic patients with HCC managed 
in the “real world” of clinical practice, documented that: a) HCC cirrhotic patients with metabolic 
disorders show a worse neoplastic picture, but this does not impact on survival probably because of a 
more preserved liver function; b) diabetes marginally reduces survival of HCC cirrhotic patients.  
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Figure Legends 
 
Figure 1. Lead-time adjusted overall survival in the 3 analyzed groups. 
Supplementary Figure 1. Lead-time adjusted overall survival in the 3 analyzed groups according 
to BCLC stage.  
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TABLES 
Table 1. Demographic, clinical and laboratory characteristics of HCC population. 
 
Patients n.        839 
  n  % 
Age, years (median, IQR)      69 (62-75) 
Female/Male 185/654 22/78 
BMI  ≥ 25 467 56 
Smoke  289 41 
Etiology  Viral 486 58 
         NAFLD 190 23 
         Alcoholic 159 19 
Child-Pugh Class A 523 66 
                               B 227 29 
                               C  43 5 
MELD ≤ 10 540 65 
BCLC class 0-A 354 44 
             B 147 18 
             C 241 30 
             D 68 8 
Laboratory tests AFP (median, IQR) 12 (5-91) 
                     Creatinine (median, IQR) 0,9 (0,72-1,04) 
                     Sodium (median, IQR) 139 (137-141) 
                     Platelets (median, IQR) 123 (84-175) 
HCC morphology Single nodule 914 51 
                        Multinodular  703 39 
                        Infiltrating 114 6 
                        Massive (> 10 cm) 59 3 
Size of largest nodule, cm  (mean, range)       3 (2-5) 
Portal vein thrombosis  144 18 
Metastasis 47 6 
Diagnosis on surveillance  430 51 
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Table 2. Characteristics of the 3 groups of HCC patients 
 
          
Variables 
Group 1  Group 2 Group 3 p values 
0-1 features 2 features 3-5 features  
Overall Outcome A Outcome B Outcome C 
(n. 347)  (n. 197) (n. 295) 
Age, years (median, IQR) 68 (57-75)  70 (63-76) 69 (64-75)  0,023 0,017 0,029 0,605 
BMI (median, IQR) 24 (21-25) 26 (24-29) 28 (26-31) <0,001 
          ≥ 25, n (%) 73 (21) 127 (64) 267 (92)      
Female/Male, n (%) 81/266 (23/77) 43/154 (22/78) 61/234 (21/79) 0,717 0,685 0,417 0,760 
Smoke, n (%) 105 (37) 65 (38) 119 (46) 0,082 0,773 0,033 0,118 
Etiology, n (%)              
Viral 254 (73) 115 (59) 117 (40) <0,001 
NAFLD 30 (9) 39 (20) 121 (41)      
Alcoholic 61 (18) 42 (21) 56 (19)         
Child-Pugh Class, n (%)           
A 200 (60) 129 (68) 194 (72) 0,008 0,044 0,007 0,130 
B 110 (33) 56 (29) 61 (23)      
C 24 (7) 5 (3) 14 (5)      
MELD ≤ 10, n (%) 204 (59) 131 (66) 205 (70) 0,011 0,076 0,003 0,417 
BCLC class, n (%)          
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A 137 (40) 89 (46) 128 (47) 0,208 0,120 0,452 0,201 
B 61 (18) 43 (22) 43 (16)      
C 111 (33) 51 (26) 79 (29)      
D 32 (9) 11 (6) 25 (9)         
Laboratory tests (median, IQR)                    
AFP   17 (6-144)  9,9 (4-51) 8 (4-78)  0,003 0,005 0,004 0,810 
Creatinine  0,85 (0,7-1) 0,9 (0,74-1,04) 0,9 (0,75-1,1)  0,026 0,177 0,007 0,312 
Sodium  139 (136-141) 139 (137-141) 140 (137-141)  0,084 0,053 0,075 0,879 
Platelets 109 (72-161) 129 (85-178) 137 (95-188)  <0,001 0,007 <0,001 0,099 
HCC morphology, n (%)          
Single nodule 157 (46) 96 (50) 150 (54) 0,248 0,303 0,137 0,591 
Multinodular  153 (44) 76 (39) 108 (39)      
Infiltrating 26 (8) 12 (6) 13 (5)      
Massive 8 (2) 9 (5) 8 (3)         
Size of largest nodule, cm (median, 
IQR) 
2,7 (1,8-4,7) 3 (2-5) 3 (2-5) 0,096 0,151 0,038 0,733 
Portal vein thrombosis, n (%) 76 (22) 28 (15) 40 (14) 0,015 0,035 0,010 0,879 
Metastases, n (%)  15 (5) 7 (4) 25 (9) 0,020 0,653 0,024 0,024 
Diagnosis on surveillance, n (%) 190 (55) 105 (54) 135 (46) 0,056 0,736 0,021 0,097 
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Table 3. Treatment options according to BCLC stage.  
 All 
Group 1 
0-1 features 
Group 2 
2 features 
Group 3 
3-5 features 
OUTCOME A 
(p value) 
OUTCOME B 
(p value) 
OUTCOME C 
(p value) 
 n    % n   % n    % n   % 
Treatment options for  BCLC 0/A (n. 354) 
 
 
  
BSC 52    15 21   16 10    11 21    17 ns ns ns 
Sorafenib 7     2 2     1 3      3 2     2 ns ns ns 
LRT & TACE 239   67 92   67 65    73 82   64 ns ns ns 
Surgery and LT 60   17 22   16 13    15 25   20 ns ns ns 
Treatment options for  BCLC B (n. 147)    
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BSC 21   15 10   17 4    10 7   17 ns ns ns 
Sorafenib 14     9 5     8 7    16 2     5 ns ns ns 
LRT & TACE 83   56 38   62 25    58 20   47 ns 0.012
 
ns 
Surgery and LT 27   18 9   15 8    19 10    23 ns ns ns 
Treatment options for  BCLC C (n. 241)    
BSC 99    43 44   42 24    50 31    39 ns ns ns 
Sorafenib 41   17 21   19 6    12 14    18 ns ns ns 
LRT & TACE 74   31 35   32 14    27 25    32 ns ns ns 
Surgery and LT 16     7 6     5 1      2 9    11 ns ns ns 
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Treatment options for  BCLC D (n. 68)    
BSC 45    69 22   71 10    91 13    57 ns ns ns 
Sorafenib 4      6 2     6 0      0 2     8 ns ns ns 
LRT & TACE 11    16 4   12 1      9 6    24 ns ns ns 
Surgery and LT 1      2 1     3 0      0 0      0 ns ns ns 
    
BSC, best supportive care; LRT, loco-regional therapy (ablation); TACE, transcatheter arterial chemoembolization, LT, liver transplantation, ns, not 
significant 
Outcome A, comparing Group 1 and Group 2; 
Outcome B, comparing Group 1 and Group 3; 
Outcome C, comparing Group 2 and the Group 3. 
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Table 4. Univariate and multivariate Cox proportional hazard regression analysis of factor affecting the lead-time adjusted survival. 
UNIVARIATE COX REGRESSION MULTIVARIATE  COX REGRESSION 
Section 1 All patients (n=839) 
  
p 
value 
HR 95% CI 
Model 1 Model 2 Model 3 
p 
value 
R
R 
95% CI 
p 
value 
HR 95% CI 
p 
value 
HR 95% CI 
Male sex 0,107 - - -                  
Age 0,192 - - -                
Etiology 0,591 - - -                
Presence of metabolic RF 0,075 - - -                
MELD score >10 
6,8E-
08 
1,76
5 
1,43
6 
2,17
0 
4,1E-
04 
1,477 
1,19
0 
1,83
3 
5,0E-
06 
1,64
4 
1,32
8 
2,03
5 
1,4E-
06 
1,73
0 
1,38
5 
2,16
1 
Multinodular or infiltrating 
HCC 
6,9E-
12 
2,12
8 
1,71
5 
2,64
0 
2,5E-
05 
1,635 
1,30
1 
2,05
4 
2,9E-
05 
1,63
6 
1,29
9 
2,06
1 
1,1E-
05 
1,70
7 
1,34
5 
2,16
6 
Size of the largest nodule 
2,2E-
08 
1,07
8 
1,05
0 
1,10
6 
0,014 1,045 
1,00
9 
1,08
1 
0,014 
1,04
4 
1,00
9 
1,08
1 
0,022 
1,04
6 
1,00
6 
1,08
7 
Diagnosis outside surveillance 
2,4E-
06 
1,64
0 
1,33
5 
2,01
5 
0,069 1,232 
0,98
4 
1,54
3 
0,120 
1,19
7 
0,95
4 
1,50
3 
0,027 
1,31
0 
1,03
2 
1,66
2 
BCLC class B-C 
3,7E-
23 
2,87
0 
2,33
0 
3,53
6 
5,9E-
13 
2,271 
1,81
7 
2,83
8 
           
Presence of portal vein 
thrombosis  
2,5E-
26 
3,50
3 
2,77
9 
4,41
5 
    
3,9E-
14 
2,60
8 
2,03
5 
3,34
4 
     
Presence of metastasis 
1,0E-
08 
2,83
7 
1,98
6 
4,05
3 
            
4,2E-
04 
1,99
2 
1,35
8 
2,92
2 
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Section 2 Group 1, 0-1 metabolic features (n=347) 
  
p 
value 
HR 95% CI 
Model 1 Model 2 Model 3 
p 
value 
HR 95% CI p value HR 95% CI p value HR 95% CI 
Male sex 0,772 - - -                  
Age 0,196 - - -                
Etiology 0,926 - - -               
MELD score >10 
6,9E-
05 
1,86
2 
1,37
1 
2,52
8 
0,003 1,633 
1,17
8 
2,26
3 
1,8E-
04 
1,84
2 
1,33
9 
2,53
4 
7,3E-
05 
1,97
6 
1,41
1 
2,76
6 
Multinodular or infiltrating 
HCC 
1,2E-
06 
2,26
8 
1,62
9 
3,15
7 
0,005 1,658 
1,16
6 
2,35
7 
0,002 
1,74
1 
1,21
9 
2,48
7 
0,002 
1,80
2 
1,25
2 
2,59
2 
Size of the largest nodule 
1,4E-
04 
1,08
6 
1,04
1 
1,13
3 
0,070 1,047 
0,99
6 
1,10
0 
0,052 
1,04
9 
1,00
0 
1,10
1 
0,051 
1,05
2 
1,00
0 
1,10
8 
Diagnosis outside surveillance 
1,4E-
04 
1,81
4 
1,33
5 
2,46
6 
0,050 1,383 
1,00
0 
1,91
2 
0,042 
1,40
2 
1,01
3 
1,94
2 
0,030 
1,46
7 
1,03
8 
2,07
3 
BCLC class B-C 
1,1E-
11 
2,96
5 
2,16
7 
4,05
6 
1,2E-
06 
2,302 
1,64
3 
3,22
3 
           
Presence of portal vein 
thrombosis  
4,0E-
11 
3,05
0 
2,19
1 
4,24
7 
    
5,4E-
06 
2,25
6 
1,58
9 
3,20
2 
     
Presence of metastasis 
8,5E-
03 
2,37
3 
1,24
6 
4,51
9 
                0,080 
1,81
2 
0,93
0 
3,52
9 
                 
UNIVARIATE COX REGRESSION MULTIVARIATE  COX REGRESSION MULTIVARIAT
E  COX 
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REGRESSION 
Section 3 Group 2, 2 metabolic features (n=197) 
  
p 
value 
HR 95% CI 
Model 1 Model 2 
  
p 
value 
HR 95% CI p value HR 95% CI 
Male sex 0,535 - - -             
Age 0,752 - - -           
Etiology 0,786 - - -           
MELD score >10 
0,018 
1,69
6 
1,09
5 
2,62
7 
0,329 1,263 
0,79
0 
2,02
0 
0,090 
1,48
8 
0,94
0 
2,35
6 
Multinodular or infiltrating 
HCC 
7,4E-
03 
1,83
5 
1,17
7 
2,86
2 
0,174 1,391 
0,86
4 
2,23
9 
0,267 
1,31
2 
0,81
3 
2,11
7 
Size of the largest nodule 
1,5E-
05 
1,13
1 
1,07
0 
1,19
5 
0,018 1,082 
1,01
4 
1,15
5 
0,052 
1,07
1 
0,99
9 
1,14
7 
Diagnosis outside surveillance 
0,007 
1,81
0 
1,17
6 
2,78
4 
0,415 1,226 
0,75
1 
2,00
2 
0,658 
1,12
0 
0,67
8 
1,84
8 
BCLC class B-C 
7,3E-
06 
2,70
7 
1,75
2 
4,18
3 
0,004 2,035 
1,25
4 
3,30
2 
      
Presence of portal vein 
thrombosis  
4,4E-
06 
3,33
1 
1,99
3 
5,56
7 
    0,007 
2,25
3 
1,25
0 
4,06
0 
Presence of metastasis 0,317 - - -             
Section 4 Group 3, 3-5 metabolic features (n=295) 
  p HR 95% CI Model 1 Model 2 Model 3 
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value p 
value 
HR 95% CI p value HR 95% CI p value HR 95% CI 
Male sex 0,055 - - -                  
Age 0,775 - - -                
Etiology 0,383 - - -                
MELD score >10 
0,018 
1,57
5 
1,08
3 
2,29
0 
0,147 0,747 
0,50
3 
1,10
8 
0,047 
1,49
1 
1,00
5 
2,21
0 
0,011 
1,68
8 
1,12
5 
2,53
3 
Multinodular or infiltrating 
HCC 
1,2E-
04 
2,08
7 
1,43
5 
3,03
6 
0,007 0,579 
0,38
9 
0,86
2 
0,007 
1,73
4 
1,16
1 
2,58
9 
0,014 
1,69
7 
1,11
4 
2,58
6 
Size of the largest nodule 
0,034 
1,05
2 
1,00
4 
1,10
2 
0,426 1,029 
0,95
9 
1,10
5 
0,319 
1,03
9 
0,96
4 
1,11
9 
0,718 
1,01
4 
0,94
1 
1,09
3 
Diagnosis outside surveillance 
0,053 - - - 0,690 1,089 
0,71
6 
1,65
5 
0,991 
1,00
3 
0,65
4 
1,53
7 
0,743 
1,07
7 
0,69
0 
1,68
1 
BCLC class B-C 
5,6E-
08 
2,79
0 
1,92
7 
4,04
0 
1,9E-
05 
2,349 
1,58
8 
3,47
4 
           
Presence of portal vein 
thrombosis  
3,2E-
11 
4,17
8 
2,73
9 
6,37
2 
    
3,3E-
07 
3,31
6 
2,09
3 
5,25
5 
     
Presence of metastasis 
2,6E-
09 
4,49
7 
2,74
2 
7,37
5 
                
8,8E-
06 
3,65
5 
2,06
4 
6,47
3 
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